Compare Pfizer Inc (PFE) vs Upstart Holdings Inc (UPST) Price & Performance

Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.

The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.

UPST trades at $24.19, up 0.71% with bearish technical signals despite recent partnership expansions. The company shows improving fundamentals with revenue growing to $1.02B in 2025 and achieving profitability with $53.6M net income. However, recent earnings misses and negative operating cash flow of -$147.73M raise concerns. Analyst sentiment remains divided with a $39.50 price target suggesting 63% upside potential from current levels.

The stock presents a high-risk opportunity with significant upside potential if the company can sustain revenue growth and improve cash flow generation. Key risks include ongoing earnings volatility, credit market sensitivity, and high debt levels. The AI lending platform's expansion into HELOC and auto lending could drive future growth, but execution remains critical for investor confidence.